Argus initiated coverage of DexCom (DXCM) with a Buy rating and $100 price target The firm sees the company maintaining above industry average growth with expanding customer reach across the continuous glucose monitoring for diabetes landscape and leveraging costs to enhance profitability. DexCom has “robust” free cash flows to support its balance sheet and enable higher than peer research and development investments to drive product innovation, the analyst tells investors in a research note. Argus sees an attractive entry point at current share levels.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom’s Strong Financial Performance and Strategic Developments Drive Buy Rating
- DexCom Earnings Call: Strong Growth Amid Challenges
- DexCom price target raised to $100 from $90 at Piper Sandler
- DexCom price target raised to $112 from $105 at Baird
- DexCom price target raised to $102 from $95 at Oppenheimer